FDA challenges stem cell therapy companies
Pete Shanks | Biopolitical Times | October 23, 2012
{{ reviewsTotal }}{{ options.labels.singularReviewCountLabel }}
{{ reviewsTotal }}{{ options.labels.pluralReviewCountLabel }}
{{ options.labels.newReviewButton }}
{{ userData.canReview.message }}
GLP Podcasts & Podcast Videos | More... |
Infographics | More... |
Infographic: Could gut bacteria help us diagnose and treat diseases? This is on the horizon thanks to CRISPR gene editing
Humans are never alone. Even in a room devoid of other people, they are always in the company of billions ...
Most Popular
- Is tilapia a human-made freak that we should avoid — or an evolutionary rockstar?
- Viewpoint: Debunking organic food myths again… and again
- 25 years of GMO crops: Economic, environmental and human health benefits
- Marrying your cousin? There may be evolutionary benefits
- Viewpoint: Should you be concerned when you read that a chemical in your food has been linked to cancer? Here’s an epidemiologist’s checklist to detect over-hyped scares
- Viewpoint: By engineering block on Vitamin A enhanced Golden Rice, Greenpeace ‘puts the whole environmental movement into disrepute’
- Viewpoint: The organic food industry is a $180 billion marketing fraud
- KFC developing world’s first bioprinted chicken nuggets for planned rollout in Russia in fall 2020
- Viewpoint: Sri Lanka’s ‘tragic’ legacy — To encourage sustainable farming, countries cannot ignore food production and socioeconomic trade-offs
- Golden Rice: The GMO crop loved by humanitarians, opposed by Greenpeace